Compare Carlyle Group Inc (CG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Zimmer Biomet Holdings Inc — how do they compare? Carlyle Group Inc trades at $47.93 (market cap $17.23B), while Zimmer Biomet Holdings Inc trades at $96.08 (market cap $18.55B). The key difference: Carlyle Group Inc and Zimmer Biomet Holdings Inc are close in size by market cap, and Carlyle Group Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| CG | ZBH | |
|---|---|---|
Market Cap | $17.23B | $18.55B |
Sector | Financials | Health |
52-Week High | $69.35 | $107.71 |
52-Week Low | $40.52 | $79.58 |
Dividend Yield | 2.9% | 0.99% |
Enterprise Value | — | $25.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carlyle Group (CG) trades at $47.87, up 0.15% today, with a bullish technical signal and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat estimates, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility from $3.4B in 2024 to $3.2B in 2025. The stock is supported by strong institutional interest and dividend payments of $0.35 per share.
The outlook is positive with analyst buy ratings at 54%, but risks include declining net income margins and negative operating cash flows. Investment opportunity lies in valuation upside to the price target, though investors should monitor earnings consistency and macroeconomic impacts on asset management.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
